Arginases play key roles in metabolic pathways. Arginase 1 (ARG1) is expressed by myeloid cells in the tumor microenvironment and suppresses the functioning of T and NK cells.
Top-line phase III results showing Hutchmed Ltd.’s targeted therapy fruquintinib reduced the risks of death and disease progression by 34% and 68%, respectively, for patients with metastatic colorectal cancer could “lay a solid foundation for Hutchmed to initiate discussions with regulatory authorities worldwide,” a spokesperson of Hutchmed, told BioWorld.
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2022, including: Akeso, PDC*Line, Starpharma, Transcenta, Zymeworks.
New and updated preclinical data presented at the Annual Congress of the European Society for Medical Oncology in Paris, including: Enlivex, GT Biopharma, Immatics, SQZ Biotechnologies.
GSK plc scientists seeking compounds with the potential to treat resistant tuberculosis infection identified a series of tetrazole agents using phenotypic screening against Mycobacterium tuberculosis.
Proto-oncogene tyrosine-protein kinase receptor Ret is a widely expressed oncogene and chromosomal rearrangements involving RET lead to fusion genes and RET kinase activation, which occur in lung cancer in about in 2% of cases of non-small cell lung cancer.
Boehringer Ingelheim Pharma GmbH & Co KG has presented data on the identification of several potent and selective tyrosine kinase inhibitors (TKIs) of HER2 that are highly active against its oncogenic exon 20 YVMA insertion mutant (HER2 YVMA), which is the most prevalent HER2 exon 20 mutation in non-small-cell lung cancer (NSCLC).
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2022, including: Adagene, Akeso, Alphamab Oncology, Astellas, Astrazeneca, Daiichi Sankyo, Eisai, I-Mab, Merck, Seagen, Starpharma, Transcenta.
RSS
